Healthcare / Medical DevicesNasdaqCM
$2.18
-0.18 (-7.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-5.5M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-121.1%
↓Gross Margin
9.4%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+0.6%
FCF CAGR
—
FCF margin
-73.0%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.3M · net income $-5.0M · FCF $-3.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $5.3M | $5.3M | $5.4M | $5.3M | $18.9M | $7.2M | $6.7M | $5.2M | $5.6M | $5.8M | $5.1M | $5.0M | $5.1M | $6.5M | $6.1M | $4.9M |
| Net Income | $-5.0M | $-5.0M | $-6.0M | $-7.1M | $-4.5M | $-7.4M | $-2.7M | $-2.4M | $-1.5M | $-908561.00 | $-1.5M | $-331410.00 | $-215660.00 | $536957.00 | $548435.00 | $157447.00 |
| EBITDA | $-4.7M | $-4.7M | $-6.0M | $-6.9M | $-3.9M | $-7.4M | $-2.6M | $-2.3M | $-1.4M | $-809746.00 | $-670669.00 | $-492376.00 | $-269076.00 | $701333.00 | $652296.00 | $-2215.00 |
| EPS | -2.16 | -2.16 | -2.84 | -4.00 | -2.88 | -4.96 | -2.08 | -2.08 | -1.36 | -0.88 | -1.60 | -0.32 | -0.24 | 0.56 | 0.64 | 0.16 |
| Gross Margin | 9.4% | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% | 26.0% | 24.8% | 31.5% | 34.9% | 29.7% | 31.1% | 32.6% | 37.5% | 37.8% | 31.1% |
| Operating Margin | -96.7% | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% | -41.0% | -46.4% | -26.6% | -16.5% | -16.1% | -13.5% | -8.7% | 7.9% | 8.3% | -2.7% |
| Net Margin | -93.6% | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% | -40.0% | -46.0% | -26.3% | -15.7% | -29.2% | -6.7% | -4.2% | 8.3% | 9.0% | 3.2% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.11 | 0.11 | 0.12 | 0.09 | 0.17 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.64 | 2.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-3.9M | $-3.9M | $-5.5M | $-5.6M | $-649000.00 | $-5.4M | $-4.3M | $-2.3M | $-1.3M | $-818943.00 | $-300338.00 | $-415984.00 | $-999507.00 | $1.1M | $-17386.00 | $187719.00 |
| Returns | ||||||||||||||||
| ROE | -121.1% | -121.1% | -90.7% | -60.9% | -54.4% | -80.7% | -18.8% | -60.1% | -33.9% | -20.2% | -28.7% | -5.9% | -3.6% | 9.2% | 11.0% | 3.6% |
| Valuation | ||||||||||||||||
| P/B | 1.22 | 1.22 | 1.38 | 1.82 | 5.66 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -1.9% | -1.9% | 1.4% | -71.7% | — | 7.6% | 28.7% | -6.5% | -3.9% | 12.7% | 3.6% | -3.1% | -20.9% | 6.4% | 24.1% | — |
| EPS Growth | 23.9% | 23.9% | 29.0% | -38.9% | — | -138.5% | 0.0% | -52.9% | -54.5% | 45.0% | -400.0% | -33.3% | -142.9% | -12.5% | 300.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.84 → -2.16
Residual
-35.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.